<DOC>
	<DOCNO>NCT00563225</DOCNO>
	<brief_summary>A multicenter , non-comparative , one arm , open , phase III study evaluate efficacy safety insulin glargine subject Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>20 Week Bridging Study Type II DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 Diabetes Mellitus diagnose least 3 year ago Treated concomitantly insulin day SU least 3 month prior study entry Treated OHA monotherapy least 1 year HbA1c great equal 7.5 % less equal 12.0 % , visit 1 ( screen visit ) BMI &lt; 40 kg/m2 No history ketonemia Women childbearing potential use medically approve contraceptive method Ability willingness perform blood glucose monitoring use blood glucose meter per requirement protocol The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>